As EMT is an increasingly recognized driver of innate and acquired resistance to various cytotoxic and targeted drugs, clinically-relevant bioavailable formulations of silibinin with proven anti-cancer activity [103,104,105] could be explored as cost-effective and feasible approaches for patients with NSCLC resistant to ALK–TKIs. This evidence concerns the gene ALK and non-small cell lung carcinoma.